Gene Therapy in SLC13A5 Deficiency, DMTs Reduce Risk of Disability in Pediatric MS, FASTEST Phase 3 Study Announced
VY-HTT01 IND Accepted, SUDEP Associated With Abnormal Cardiac Response, Humoral Response in MS DMTs Identified